Molecular Partners published the invitation to the Annual General Meeting 2019.

Molecular Partners published its audited Financial Results for 2018 and the company’s 2018 Annual Report.

In its presentation at the Cowen and Company 39th Annual Healthcare Conference, Molecular Partners highlights the progress on its clinical DARPin® compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin® molecules targeting peptide MHC complexes supported by Gilead

Molecular Partners announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for abicipar as well as the initiation of a strategic collaboration with Amgen in the field of immuno-oncology, two key milestones for the company.

Company highlights recent progress on clinical DARPin® compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310.

Molecular Partners and Amgen announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).

Molecular Partners announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together with its partner Allergan on the company’s R&D Day in New York.

Molecular Partners will present new data on its immuno-oncology pipeline at upcoming scientific conferences.

Molecular Partners published its Interim Management Statement for the period ending September 30, 2018, highlighting positive phase 3 efficacy data for abicipar, the ongoing clinical trials for MP0250 in oncology as well as further advancement of the immuno-oncology pipeline of the company.

Phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. These data underline that abicipar has the potential to become the first fixed 12-week anti-VEGF therapeutic.